Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential.

Krause, Philip R; Fleming, Thomas R; Ellenberg, Susan S; Henao-Restrepo, Ana Maria

Krause, Philip R; Fleming, Thomas R; Ellenberg, Susan S; Henao-Restrepo, Ana Maria.

Krause PR; Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Fleming TR; University of Washington, Fred Hutchinson Cancer Centre, Seattle, WA, USA.
Ellenberg SS; Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Henao-Restrepo AM; Health Emergencies Programme, World Health Organization, CH-1211 Geneva 27, Switzerland. Electronic address: henaorestrepoa@who.int.

Lancet ; 396(10263): 1611-1613, 2020 11 21.

Article in English | MEDLINE | ID: covidwho-894283

Subject(s)

Clinical Trials as Topic/standards; Confidentiality; Coronavirus Infections/prevention & control; Pandemics/prevention & control; Pneumonia, Viral/prevention & control; Viral Vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Viral Vaccines / Clinical Trials as Topic / Coronavirus Infections / Confidentiality / Pandemics Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Lancet Year: 2020 Document Type: Article Affiliation country: S0140-6736(20)32259-5

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google